Parliamentary questions

1122. Deputy Ken O'Flynn asked the Minister for Health the number of patients in the State known to the HSE or the Department of Health who are clinically eligible for treatment with omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia; and if this number has informed any budget impact assessment. [32772/26]

1123. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a target timeline for completing reimbursement decisions in respect of orphan medicines or medicines for progressive rare diseases; and if no such target exists, whether one is under consideration. [32773/26]

1124. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any escalation process where a reimbursement application concerns a progressive neurological condition in which delay may lead to irreversible deterioration. [32774/26]

1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]

1126. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has examined the favourable reimbursement opinion issued in France for Skyclarys in Friedreich’s ataxia, and whether such international assessments are considered in Irish rare disease reimbursement decisions. [32776/26]

1127. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE is aware that Italy’s medicines authority approved reimbursement of Skyclarys for Friedreich’s ataxia in December 2025, and whether this decision has been considered in the Irish process. [32777/26]

1128. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has received a commercial proposal from Biogen Idec Ireland Limited in respect of omaveloxolone, marketed as Skyclarys, since 16 April 2026; and if not, what steps the HSE is taking to progress the matter. [32778/26]

1129. Deputy Ken O'Flynn asked the Minister for Health whether any statutory, contractual, policy or administrative time limits apply where a marketing authorisation holder has been invited to submit a commercial proposal for a medicine but has not yet done so. [32779/26]

1130. Deputy Ken O'Flynn asked the Minister for Health whether she will consider introducing a formal interim access pathway for rare disease medicines where a treatment has European marketing authorisation, there is no alternative disease-modifying therapy available, and the reimbursement process remains unresolved. [32780/26]

1131. Deputy Ivana Bacik asked the Minister for Health if she is aware that the HSE is in ownership of a swimming pool facility at Elm Park, Dublin 4; and her plans to ensure that it be preserved to provide additional swimming facilities for the local community. [32789/26]

1132. Deputy Pearse Doherty asked the Minister for Health the reason an internal review has not been commissioned regarding one of two complaints (details supplied) submitted to St. James’s Hospital, Dublin; and if she will make a statement on the matter. [32790/26]

1133. Deputy Barry Heneghan asked the Minister for Health whether her Department has examined the practice of pharmacies charging additional fees for dispensing medications in blister packs where this is clinically required, particularly for older persons with complex medication regimes; whether any guidance or regulation exists governing such charges under the community drug schemes; if considera…

1134. Deputy Barry Ward asked the Minister for Health the position regarding any research being carried out into the viability of providing treatment for people suffering from Friedrichs ataxia in Ireland; and if she will make a statement on the matter. [32792/26]

1135. Deputy Barry Ward asked the Minister for Health the position regarding any engagement she has had with families or support groups for people suffering from Friedrichs ataxia in Ireland; and if she will make a statement on the matter. [32793/26]

1136. Deputy Barry Ward asked the Minister for Health the position regarding the approval process for skyclarys as a treatment for Friedrichs ataxia; and if she will make a statement on the matter. [32794/26]

1137. Deputy Barry Ward asked the Minister for Health her views on whether the delays in the approval of skyclarys as a treatment for Friedrichs ataxia aligns with the "equitable access" as outlined in the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [32795/26]

1138. Deputy Emer Currie asked the Minister for Health if a matter (details supplied) will be clarified; and if she will make a statement on the matter. [32813/26]

1139. Deputy Sorca Clarke asked the Minister for Health the level of funding allocated to Mental Health Services in County Donegal in the years of 2024, 2025 and 2026, in tabular form. [32815/26]

1140. Deputy Sorca Clarke asked the Minister for Health if each model 4 hospital accident and emergency department has mental health nursing staff on site after 5pm on weekdays and on weekends and bank holidays; the number of WTE mental health staff that are available for each of those model 4 hospitals, in tabular form. [32817/26]

1141. Deputy Sorca Clarke asked the Minister for Health the number of WTE registrars in plastic surgery based at the Mater Hospital as of 28 April 2026, in tabular form. [32818/26]

1142. Deputy Sorca Clarke asked the Minister for Health the level of funding allocated to mental health services in County Louth in each of the years of 2024, 2025 and 2026, in tabular form. [32819/26]

1143. Deputy Sorca Clarke asked the Minister for Health the number of WTE dental nurses and dental hygienists posts filled at Longford dental clinic as of 29 April 2026, in tabular form. [32820/26]

1144. Deputy Colm Burke asked the Minister for Health whether Ireland intends to use its Presidency of the Council of the European Union to advocate for the inclusion of provisions within any revised tobacco products directive that would permit member states to introduce generational tobacco sales restrictions, similar to those enacted in the United Kingdom under the Tobacco and Vapes Act 2025; wh…

1145. Deputy Colm Burke asked the Minister for Health whether her Department has submitted Ireland's health priorities for inclusion in the eighteen-month Trio Presidency programme being developed with Lithuania and Greece; if so, whether she will outline those priorities; whether the programme will address the regulation of tobacco and novel nicotine products; and if she will make a statement on …

1146. Deputy Colm Burke asked the Minister for Health whether Ireland intends to seek Council conclusions on tobacco control during its Presidency; if so, the proposed scope of such conclusions; whether such conclusions would address the regulatory treatment of novel nicotine products; and whether she has consulted with other Member States on this matter. [32833/26]